Sai Life Sciences

About the Company

Sai Life Sciences Limited, established in 1999, is a contract research, development, and manufacturing organization (CRDMO) providing services in drug discovery, development, and manufacturing. The company offers capabilities in chemistry, manufacturing, and control (CMC) and contract research (CRO) for small-molecule new chemical entities. It serves over 280 pharmaceutical companies and operates globally, with facilities in the US, UK, and India. The company employs over 2,300 scientific staff and has received multiple regulatory approvals from authorities including the USFDA and CDSCO.

Strengths

• Integrated Indian CRDMO offering discovery, development, and manufacturing services.
• Portfolio includes 50 late-phase and commercial products as of September 30, 2024.
• Diverse mix of commercial drugs and under-development molecules with blockbuster potential.
• CRDMO model enables proximity-based development and manufacturing in India.
• Broad customer base, including top global pharmaceutical companies.

Risks

• Dependence on biotechnology and pharmaceutical customers subject to market and funding risks.
• R&D outcomes may fail to meet customer expectations, leading to project discontinuation.
• Low success rate in drug development impacts overall financial performance.
• Risks from international operations, including delays and regulatory challenges.
• Loss-making subsidiaries may adversely impact overall financials.
• Pricing pressure from customers may affect margins and profitability.
• High working capital requirements could strain financial resources.
• No proceeds from the Offer for Sale portion will benefit the company.